The global cancer immunotherapy market is expected to exceed US$ 145 billion by 2022, registering a compound annual growth rate (CAGR) of more than 14% during the forecast period. The rise in the incidence rate of cancer worldwide, increase in adoption of immunotherapy over other treatment options, and development of bioinformatics tools to enhance drug development process are expected to drive the market. However, the high cost of treatment is of hampering the growth of the cancer immunotherapy market.
In this report, the global cancer immunotherapy market is segmented by type, application, end user, and region. On the basis of type, the market is segmented into immunomodulators, checkpoint inhibitors, cancer vaccines, and monoclonal antibodies. The market on the basis of application is segmented into melanoma, colorectal cancer, prostate cancer, head and neck cancer, breast cancer, and lung cancer. On the basis of end user, the market is segmented into hospitals and clinics & others. The hospitals segment of the cancer immunotherapy market accounted for the largest share in 2016 due to the increasing use of immunotherapy drugs in hospitals.
The global cancer immunotherapy market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market in 2016. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional cancer immunotherapy market and analyzes the variations in the growth of the industry in certain regions.
A glimpse of the report structure is provided in the report description available on the website.
Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.) are the most active players in the cancer immunotherapy market.
This report covers the cancer immunotherapy market, in terms of value, and forecasts the market size till 2022. In addition, the report identifies key growth segments and opportunities in the industry. This report also covers detailed competitive outlook including the share and company profiles of the key players in the global market. Company profile includes company summary, financial summary, business strategy and planning, SWOT analysis, and current developments.
The deep-dive study on the cancer immunotherapy market will help customers with the identification of new market opportunities and targeted promotional plans.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com